Your browser does not support SVG.
HOME
PIPELINE
LEADERSHIP
Management Team
Board of Directors
DISEASES
Acne vulgaris
Atopic dermatitis
Hyperhidrosis
Psoriasis
Vitiligo
NEWS
CAREERS
CONTACT
RVT-502
RVT-502
December 3, 2019
Dermavant Announces First Patient Dosed in Phase 2 ...
Read More
December 6, 2018
Dermavant Sciences to Present New Data on Cerdulat ...
Read More
Recent Posts
Dermavant Appoints Chris Chapman as Chief Commercial Officer
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
Archives
January 2020
December 2019
June 2019
May 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
April 2018
September 2017
July 2017
December 2016
November 2015
Categories
Dermavant Sciences
News
RVT-201
RVT-501
RVT-502
RVT-504
Tapinarof
